Antiretroviral Options for Naïve and Virologically Controlled Patients
1. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2009. Available at:
www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 1 September 2011).
2. European AIDS Clinical Society, Guidelines : Clinical management and treatment of HIV infected adults in Europe. Available at:
www.europeanaidsclinicalsociety.org/images/ stories/EACS-Pdf/1_treatment_of_hiv_infected_adults.pdf (accessed 1 September 2011).
3. Recommandations du groupe d’experts 2010, Prise en charge médicale des personnes infectées par le VIH. Available at:
www.sante.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_ charge_medicale_des_personnes_infectees_par_le_VIH_ sous_la_direction_du_Pr-_Patrick_Yeni.pdf (accessed 1 September 2011).
4. Ait-Khaled M, Stone C, Amphlett G, et al., M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine, AIDS, 2002;16(12):1686–9.
5. Cassetti I, Madruga JV, Etzel A, et al., The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naïve patients through seven years, Abstract TUPE0057, Presented at: the 17th International AIDS Conference, Mexico City, Mexico, 3–8 August 2008.
6. Arribas JR, Pozniak AL, Gallant JE, et al., Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis, J Acquir Immune Defic Syndr, 2008;47(1):74–8.
7. Lennox JL, DeJesus E, Lazzarin A, et al., Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, Lancet, 2009;374(9692):796–806.
8. Molina JM, Andrade-Villanueva J, Echevarria J, et al., Once- daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study, Lancet, 2008;372(9639):646–55.
9. Ortiz R, Dejesus E, Khanlou H, et al., Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48, AIDS, 2008;22(12):1389–97.
10. Molina JM, Podsadecki TJ, Johnson MA, et al., A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks, AIDS Res Hum Retroviruses, 2007;23(12):1505–14.
11. Sax P, Tierney C, Collier AC, et al., AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir- emtricitabine for initial HIV-1 therapy, N Engl J Med, 2009;361(23):2230–40.
12. Smith KY, Patel P, Fine D, et al., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment, AIDS, 2009;23(12):1547–56.
13. Zimmermann AE, Pizzoferrato T, Bedford J, et al., Tenofovir- associated acute and chronic kidney disease: a case of multiple drug interactions, Clin Infect Dis, 2006;42(2):283–90.
14. Karras A, Lafaurie M, Furco A, et al., Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus, Clin Infect Dis, 2003;36(8):1070–3.
15. Moore R, Keruly J, Gallant J. Tenofovir and renal dysfunction in clinical practice, Abstract 832, Presented at: the 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, CA, 25–28 February 2007.
16. Mocroft A, Kirk O, Reiss P, et al; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, 2010;24(11):1667–78.
17. Mallal S, Phillips E, Carosi G, et al., HLA-B*5701 screening for hypersensitivity to abacavir, N Engl J Med, 2008;358(6):568–79.
18. Saag M, Balu R, Phillips E, et al., High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients, Clin Infect Dis, 2008;46(7):1111–8.
19. Sabin CA, Worm SW, Weber R, et al., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Lancet, 2008;371(9622):1417–26.
20. Lang S, Mary-Krause M, Cotte L, et al; Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital
Database on HIV ANRS cohort CO4, Arch Intern Med, 2010;170(14):1228–38.
21. Staszewski S, Morales-Ramirez J, Tashima KT, et al., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team, N Engl J Med, 1999;341(25):1865–73.
22. Gulick RM, Ribaudo HJ, Shikuma CM, et al., Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection, N Engl J Med, 2004;350(18):1850–61.
23. Riddler SA, Haubrich R, DiRienzo AG, et al., Class-sparing regimens for initial treatment of HIV-1 infection, N Engl J Med, 2008;358(20):2095–106.
24. Haubrich RH, Riddler SA, DiRienzo AG, et al., Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment, AIDS, 2009;23(9):1109–18.
25. Squires K, Lazzarin A, Gatell JM, et al., Comparison of once- daily atazanavir with efavirenz, each in combination with fixed- dose zidovudine and lamivudine, as initial therapy for patients infected with HIV, J Acquir Immune Defic Syndr, 2004;36(5):1011–9.
26. Lundgren J, Reiss P, Worm S, et al., Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: The D:A:D Study, Abstract Paper 44 LB, Presented at: the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8–11 February 2009.
27. Hirsch MS, Gunthard HF, Schapiro JM, et al., Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel, Clin Infect Dis, 2008;47(2):266–85.
28. Lennox J, DeJesus E, Lazzarin A, et al., Raltegravir demonstrates durable efficacy through 96 weeks: Results from STARTMRK, a Phase III study of raltegravir-based vs. efavirenz- based therapy in treatment-naïve HIV+ patients, Abstract H924b, Presented at: the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 12–15 September 2009.
29. van Leth F, Phanuphak P, Ruxrungtham K, et al., Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study, Lancet, 2004;363(9417):1253–63.
30. Soriano V, Köppe S, Mingrone H, et al., Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results, Abstract LBPEB07, Paper presented at 5th IAS Conference on HIV Pathogenesis; Treatment and Prevention, Cape Town, South Africa, 19–22 July 2009.
31. van Leth F, Andrews S, Grinsztejn B, et al., The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART, AIDS, 2005;19(5):463–71.
32. Bristol Myers Squibb. Sustiva September 2009 Prescribing Information, 2009. Available at:
www.accessdata.fda.gov/drugsatfda_docs/label/2009/ 020972s033,021360s021lbl.pdf (accessed 1 September 2011).
33. Mills AM, Nelson M, Jayaweera D, et al., Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis, AIDS, 2009;23(13):1679–88.
34. Walmsley S, Bernstein B, King M, et al., Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection, N Engl J Med, 2002;346(26):2039–46.
35. Murphy RL, da Silva BA, Hicks CB, et al., Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients, HIV Clin Trials, 2008;9(1):1–10.
36. Squires KE, Johnson M, Yang R, et al., Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study, J Antimicrob Chemother, 2011;66(2):363–70.
37. Malan DR, Krantz E, David N, et al., Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral- naïve patients, J Acquir Immune Defic Syndr, 2008;47(2):161–7.
38. Molina J, Andrade-Villanueva J, Echevarria J, et al., CASTLE: Atazanavir-ritonavir vs. lopinavir-ritonavir in antiretroviral- naïve HIV-1 infected patients: 96 week efficacy and safety, Abstract H-1250d, Presented at: the 48th ICAAC/46th IDSA Meeting, Washington, DC, 25–28 October 2008.
39. Chan-Tack KM, Truffa MM, Struble KA, et al., Atazanavir- associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System, AIDS, 2007;21(9):1215–8.
40. Prezista, HIGHLIGHTS OF PRESCRIBING INFORMATION. Available at:
www.accessdata.fda.gov/drugsatfda_docs/ label/2010/021976s012s013lbl.pdf (accessed 1 September 2011).
41. Eron J Jr, Yeni P, Gathe J Jr, et al., The KLEAN study of
fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial, Lancet, 2006;368(9534):476–82.
42. Pulido F, Estrada V, Baril JG, et al., Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks, HIV Clin Trials, 2009;10(2):76–87.
43. Walmsley S, Avihingsanon A, Slim J, et al., Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults, J Acquir Immune Defic Syndr, 2009;50(4):367–74.
44. Shimura K, Kodama E, Sakagami Y, et al., Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137), J Virol, 2008, 82:764–74.
45. Saag M, Ive P, Heere J, et al., A multicenter, randomized, double blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine/lamivudine), for the treatment of antiretroviral- naïve subjects infected with R5 HIV: week 48 results of the MERIT study, Abstract MOPEB016, Presented at: the 4th IAS Conference on HIV Pathogenesis; Treatment and Prevention, Sydney, Australia, 22–25 July 2007.
46. Heera J, Ive P, Botes M, et al., The MERIT study of maraviroc in antiretroviral-naïve patients with R5 HIV-1: 96-weeks results, Abstract TUAB103, Presented at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; Cape Town, South Africa, 19–22 July 2009.
47. Reynes J, Lawal A, Pulido F, et al., Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve HIV-1 infected subjects, Abstract 5384, Presented at: the XVIII International AIDS conference, Vienna, Austria, 18–23 July 2010.
48. Kozal MJ, Lupo S, DeJesus E, et al, for the SPARTAN study team, The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg BID plus raltegravir (RAL) 400mg BID (ATV+RAL) in treatment-naïve HIV- infected subjects IAS, Abstract 17423, Presented at: the XVIII International AIDS conference, Vienna, Austria, 18–23 July 2010.
49. Mills A, Mildvan D, Podzamczer D, et al., Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine 200mg/tenofovir 300mg QD (TDF/FTC) + ATV/r in treatment-naïve patients infected with CCR5-tropic HIV-1 (Study A4001078): A week 24 planned interim analysis, Abstract 17280, Presented at: the XVIII International AIDS conference, Vienna, Austria, 18–23 July 2010.
50. Flandre P, Delaugerre C, Ghosn J, et al., MONARK Study Group. Prognostic factors for virological response in antiretroviral therapy-naïve patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone, Antivir Ther, 2009;14(1):93–7.
51. Eron JJ, Young B, Cooper DA, et al., SWITCHMRK 1 and 2 investigators; Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials, Lancet, 2010;375(9712):396–407.
52. Martínez E, Larrousse M, Llibre JM, et al., SPIRAL Study
Group.Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study, AIDS, 2010;24(11):1697–707.
53. Squires KE, Young B, Dejesus E, et al., ARIES study team., Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients, AIDS, 2010;24(13):2019–27.
54. Gatell J, Salmon-Ceron D, Lazzarin A, et al., SWAN Study Group. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results, Clin Infect Dis, 2007;44(11):1484–92.
55. Meynard JL, Bouteloup V, Landman R, et al., on behalf of the KALESOLO Study Group, Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial, J Antimicrob Chemother, 2010 Nov;65(11):2436–44.
56. Arribas JR, Delgado R, Arranz A, et al., OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis, J Acquir Immune Defic Syndr, 2009;51(2):147–52.
57. Katlama C, Valantin MA, Algarte-Genin M, et al., Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136, AIDS, 2010;24(15):2365–74.
EUROPEAN INFECTIOUS DISEASE
79
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92